<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR26">
 <label>26.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Aayisha</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Devi</surname>
    <given-names>TSR</given-names>
   </name>
   <name>
    <surname>Janani</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Muthu</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Raja</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Sevvanthi</surname>
    <given-names>S</given-names>
   </name>
  </person-group>
  <article-title>DFT, molecular docking and experimental FT-IR, FT-Raman, NMR inquisitions on “4-chloro-
   <italic>N</italic>-(4,5-dihydro-1
   <italic>H</italic>-imidazol-2-yl)-6-methoxy-2-methylpyrimidin-5-amine”: alpha-2-imidazoline receptor agonist antihypertensive agent
  </article-title>
  <source>J Mol Struct</source>
  <year>2019</year>
  <volume>1186</volume>
  <fpage>468</fpage>
  <lpage>481</lpage>
  <pub-id pub-id-type="doi">10.1016/j.molstruc.2019.03.056</pub-id>
 </element-citation>
</ref>
